<?xml-stylesheet type="text/xsl" href="https://emersonexchange365.com/cfs-file/__key/system/syndication/rss.xsl" media="screen"?><rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" xmlns:wfw="http://wellformedweb.org/CommentAPI/"><channel><title>Life Sciences Blog - All Comments</title><link>/industries/lifesciences/b/life-sciences-blog</link><description /><dc:language>en-US</dc:language><generator>Telligent Community 13</generator><item><title>RE: Continued Process Verification in the Process Validation Lifecycle</title><link>https://emersonexchange365.com/industries/lifesciences/b/life-sciences-blog/posts/continued-process-verification-in-the-process-validation-lifecycle</link><pubDate>Thu, 19 Feb 2015 17:17:51 GMT</pubDate><guid isPermaLink="false">cd40bb2b-3d49-4868-939d-417119b40291:bcb8b302-f616-4e58-b8e1-e518bf17c0ec</guid><dc:creator>Victor OBrien</dc:creator><slash:comments>0</slash:comments><description>&lt;p&gt;Has the FDA has given any indication that it will beyond just requesting statistical analysis and science-based proof of a state of control to actually expecting it? &lt;/p&gt;
&lt;p&gt;Also, you mentioned a lot about stages 2 and 3 and how challenging it is to implement a design space at those stages. What do you think creates those challenges? &amp;nbsp;&lt;/p&gt;
&lt;img src="https://emersonexchange365.com/aggbug?PostID=3909&amp;AppID=93&amp;AppType=Weblog&amp;ContentType=0" width="1" height="1"&gt;</description></item></channel></rss>